- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
February 27-29, 2008, The Venetian, Las Vegas
Medtech Insight, a division of Windhover Information, Inc. and a leading provider of business information for the medical device industry, has announced that 49 promising early- to late-stage medical device companies seeking funding and/or strategic partnership are currently confirmed to present at its "Investment In Innovation (In3) West" conference, being held February 27-29 at The Venetian Resort-Hotel-Casino in Las Vegas, Nevada. The two-day In3 West event (www.windhover.com/in3west08) - the company's 29th In3 conference - will showcase a carefully selected group of 50+ innovative young medtech companies from around the world presenting (many for the first time on our stage) to an audience of 250+ senior business development and investment executives from the leading medical technology and healthcare investment firms from around the world, for purposes of raising funding or forming strategic partnerships.
Presentations from this group of cutting-edge, early- to late-stage companies will encompass a wide variety of high-growth device sectors, including cardiovascular therapeutics and diagnostics/interventional cardiology, diagnostics, drug delivery, imaging, minimally invasive surgery, nanotechnology, neurostimulation, oncology, orthopedics/spine, peripheral vascular, stem cells, stroke management, tissue engineering, and wound management, to mention only a few. Presenters confirmed to date include Advanced Headache Intervention, Angel Medical Systems, BioTelligent, Bone Biologics, Cardiac Output Technologies, Ceragenix Pharmaceuticals, Cohera Medical, CoreSpine Technologies, Crospon, CVAC Systems, Deca-Medics, eCardio Diagnostics, EMKinetics, HealthLink Europe, HemoBioTech, Infrared Sciences, Innovent Medical Solutions, Intellwave, Interventional and Surgical Innovations, Light Sciences Oncology, Med-Conduit, Minnow Medical, mNemoscience, Moerae Matrix, Nerites, Nesos Health, Novian Health, Photo Dynamic Therapy, PolyRemedy, Portland Orthopaedic, Praxim, Provista Life Sciences, Seno Medical Instruments, Sunshine Heart Company, ThermopeutiX, Tissue Genetics, Ultimate Spine, ValveXchange, VeinAid, Veran Medical, Victhom Human Bionics, Visualase, Vivoxid, Xylos Corporation, and Zassi Medical Evolutions, among others being added to the program regularly.
The In3 West format will include focused 10-minute presentations by a senior executive from each presenting company to our full audience, each followed immediately by one-on-one meetings with interested parties in private breakout rooms. The event will also feature a presenting company product exhibition/networking reception, a Buyers' Perspective panel discussion/case study titled "What Are Buyers Looking for in 2008?," a Venture Perspective panel discussion/case study, "Doing Innovative or Unconventional Deals," a workshop presented by Christopher Velis of Medical Capital Advisors entitled "10 Things Every Medical Technology Entrepreneur Should Know," and much more. Attendees registering to attend In3 West can save $100 before Thursday, January 31st.
Event co-sponsors include AdvaMed, Battelle, Business Wire, Curran International, MDMA, Medmarc and The Hartford, Medical Capital Advisors, The MedTech Group, and Ronald Trahan Associates.
The growing In3 West attendee list includes a robust line-up of buy-side/investors. A sample of companies sending their teams include: 3M, Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Aubrey Group, Inc., Baird Venture Partners, Baxter Healthcare Corporation, Becton Dickinson & Co., Boston Scientific Corporation, Cardinal Health, Cook, C.R. Bard, Inc., Clarus Ventures, Ethicon, Ethicon Endo-Surgery, Inc., ev3 Inc., Frazier Healthcare Ventures, Galen, Hercules Technology Growth Capital, InterWest Partners, Johnson & Johnson Development Corp., Kimberly-Clark Health Care, Kobayashi Pharmaceuticals of America, Longitude Capital, Medtronic, MedVenture Technology Corporation, Musculoskeletal Transplant Foundation, Numenor Ventures LLC, Olympus Medical, Prism Venture Partners, Prospect Venture Partners, Queensland BioCapital Funds, Sante Ventures, Special Situations Life Sciences Fund, Stryker, SV Life Sciences, SVB Capital, Synergy Life Science Partners, Synthes Spine, Teijin America, Teijin Pharma, Ltd., Teleflex, The Integra Group, Thoratec, Triathlon Medical Ventures, and Western Technology Investment, among many others.
Medtech Insight and its parent company, Windhover Information, have established a reputation as holding the premier forums worldwide for discerning senior executives in the medical device, diagnostics, biotech, and pharmaceutical business development and investment communities to meet and screen promising early-stage life sciences companies in need of funding, acquisition and/or strategic partnership, and to network with key decision makers in the industry. Over 1300 emerging medical technology company presenters and over 7000 attendees have participated at In3 events over the past 7 years.
Visit www.medtechinsight.com/pastpresenters.html for a full list of previous Medtech Insight conference presenters and their technology descriptions. To read what past attendees and industry experts think of Medtech Insight's investment and partnering events, please visit www.medtechinsight.com/in3success.html.
The company's Spring 2008 "Investment In Innovation" event -- In3 Europe -- will take place in Paris, France at the Hilton Paris, April 29-30. Visit www.windhover.com/in3europe08 for regularly updated information on this exciting international event.
About Medtech Insight
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace.
For more information, please click here
Medtech Insight, a division of Windhover Information Inc.
Kristy Grimes, 480-985-9512
or 888-202-5939 toll-free in the U.S.
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016